Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ProQR Therapeutics (PRQR) Income from Continuing Operations (2021 - 2025)

Historic Income from Continuing Operations for ProQR Therapeutics (PRQR) over the last 5 years, with Q3 2025 value amounting to -$13.2 million.

  • ProQR Therapeutics' Income from Continuing Operations fell 3781.35% to -$13.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$49.2 million, marking a year-over-year decrease of 6988.18%. This contributed to the annual value of -$30.0 million for FY2024, which is 15.84% down from last year.
  • Latest data reveals that ProQR Therapeutics reported Income from Continuing Operations of -$13.2 million as of Q3 2025, which was down 3781.35% from -$13.9 million recorded in Q2 2025.
  • ProQR Therapeutics' Income from Continuing Operations' 5-year high stood at -$3.9 million during Q2 2024, with a 5-year trough of -$20.0 million in Q3 2022.
  • For the 5-year period, ProQR Therapeutics' Income from Continuing Operations averaged around -$12.7 million, with its median value being -$12.7 million (2022).
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first soared by 5974.5% in 2023, then tumbled by 25765.03% in 2025.
  • Over the past 5 years, ProQR Therapeutics' Income from Continuing Operations (Quarter) stood at -$19.8 million in 2021, then skyrocketed by 35.87% to -$12.7 million in 2022, then surged by 46.95% to -$6.7 million in 2023, then plummeted by 59.73% to -$10.8 million in 2024, then decreased by 22.46% to -$13.2 million in 2025.
  • Its Income from Continuing Operations was -$13.2 million in Q3 2025, compared to -$13.9 million in Q2 2025 and -$11.4 million in Q1 2025.